ERBB2 and breast carcinoma: In a model of HER2+ breast cancer, the combination of chemotherapy and a whole cell vaccine generated from tumor cells expressing the oncogene Neu and GM-CSF, delayed tumor growth by activating an anti-tumor T cell response [130].